Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nymox Pharmaceutical, a biopharmaceutical company, has announced that the company's latest multi-center US study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia, is nearing completion.
Subscribe to our email newsletter
The company anticipates the reporting of final results and statistical analysis for the study within the next two to three weeks. The new study concerns assessment of the one year efficacy effects of a single treatment of NX-1207.
NX-1207 has entered its Phase III development program, the last stage before filing with the FDA for approval. The drug involves a new targeted approach to the treatment of benign prostatic hyperplasia (BPH).